SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Virbamec Super 10 mg/ml, 100 mg/ml Solution for Injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active substances

Ivermectin 10 mg/ml

Clorsulon 100 mg/ml

3. PHARMACEUTICAL FORM

Solution for injection.

Clear, slightly yellow and slightly viscous solution.

4. CLINICAL PARTICULARS

4.1 Target species

Cattle.

4.2 Indications for use, specifying the target species

For the treatment of mixed trematode and nematode or arthropod infestations, due to adult and immature roundworms, lungworms, warbles, mites, lice and liver fluke in cattle.

Gastro-intestinal roundworms(adult and fourth-stage larvae):

Ostertagia ostertagi(including inhibited larval stages)

O. lyrata

Haemonchus placei

Trichostrongylus axei

Trichostrongylus colubriformis

Cooperia oncophora

Cooperia punctata

Cooperia pectinata

Bunostomum phlebotomum

Oesophagostomum radiatum

Strongyloides papillosus (adult)

Nematodirus helvetianus (adult)

Nematodirus spathiger (adult)

Lungworms(adult and fourth-stage larvae):

Dictyocaulus viviparus

Liver fluke(adult):

Fasciola hepatica

Warbles(parasitic stages):

Hypoderma bovis

Hypoderma lineatum

Mange mites:

Psoroptes bovis

Sarcoptes scabieivar. bovis

Sucking lice:

Linognathus vituli

Haematopinus eurysternus

The product may also be used as an aid in the control of the mange mite Chorioptes bovis, but complete elimination may not occur.

4.3 Contra-indications

Do not use in non-lactating dairy cows including pregnant heifers within 60 days of calving.

Not for use in species other than cattle as severe adverse reactions, including fatalities, may occur in dogs for example.

Do not use by the intravenous or intramuscular route.

Do not use in animals known to be hypersensitive to the active substance.

4.4 Special warnings for each target species

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used”.

i) Special precautions for use in animals

Divide doses greater than 10 ml between two injection sites to reduce occasional discomfort or site reaction.

The timing of treatment for the parasitic stages of warbles should be chosen carefully. The best time to treat against infections with Hypodermais immediately after the end of the swarming of the warbles, before the larvae cause damage in the body of the animal (October to November). If larvae of Hypoderma bovisare killed during migration through the spine, this may induce posterior paralysis and recumbency. These reactions occur mainly when animals are treated between December and March.

Avermectins may not be well tolerated in non-target species. Cases of intolerance resulting in fatalities have been reported in dogs, especially collies, old English sheep dogs and related breeds or crosses and also in turtles/tortoises.

ii) Special precautions to be taken by the person administering the veterinary medicinal product to animals

Do not smoke, drink or eat while handling the product.

Wash hands after use.

Avoid contact with skin and eyes.

Take care to avoid self-administration, the product may cause irritation and/or pain at the site of injection.

iii) Other precautions

Ivermectin is highly toxic to aquatic invertebrates. Treated cattle should not have direct access to ponds, streams or ditches for 14 days after treatment to avoid adverse effects on aquatic organisms.

4.6 Adverse reactions (frequency and seriousness)

Transitory discomfort has been observed in some cattle following subcutaneous administration. Soft-tissue swelling and/or slight pain at the injection site has also been observed. These reactions have disappeared without treatment. In case of hypersensitivityreactionsa symptomatictreatmentshouldbeapplied

Do not use in animals producing milk for human consumption.

Do not use in non-lactating dairy cows including pregnant heifers within 60 days of calving.

4.8 Interaction with other medicinal products and other forms of interaction

Not known.

4.9 Amounts to be administered and administration route

The product should be given once by subcutaneous injection at the recommended dosage level of 200 mcg of ivermectin and 2 mg of clorsulon per kilogram of bodyweight. Each ml contains 10 mg of ivermectin and 100 mg of clorsulon, sufficient to treat 50 kg of bodyweight. Subcutaneous injection only.

To ensure administration of a correct dose, bodyweight should be determined as accurately as possible; accuracy of the dosing device should be checked.

If animals are to be treated collectively rather than individually they should be grouped according to their bodyweight and dosed accordingly, in order to avoid under- or over‑dosing.

Divide doses greater than 10 ml between two injection sites.

Inject under the loose skin behind the shoulder. Use of a 17-gauge, ½-inch (15-20 mm) needle is suggested. The injection may be given with any standard automatic, multidose or single-dose hypodermic syringe. If using a hypodermic syringe, use a separate sterile needle to withdraw the dose from the pack.

This product does not contain an antimicrobial preservative. Swab septum before removing each dose. Use a dry, sterile needle and syringe.

For 200, 500 and 1000-ml pack sizes, use only automatic-syringe equipment.

Injection on animals with wet or dirty hides is not recommended.

When the temperature of the product is below 5 °C, difficulty in administration may be encountered due to increased viscosity. Warming the product and injection equipment to about 15 °C will greatly increase the ease with which the product can be injected. Different injection sites should be used for other parenteral products.

The timing for treatment should be based on epidemiological factors and should be customised for each individual farm. A dosing programme should be established by the veterinary surgeon.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

An acute toxic syndrome consisting of CNS signs of depression and listlessness, ataxia, recumbency and possible death occurs in cattle given SC. doses equal to 40 times the therapeutic dose for ivermectin. Treatment should be symptomatic.

A toxic-syndrome dose level has not been identified in cattle for clorsulon.

4.11 Withdrawal periods

Meat and offal : 66 days.

Milk: do not use in animals producing milk for human consumption.

Do not use in non-lactating dairy cows including pregnant heifers within 60 days of calving.

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group:endectocide, anthelmintic Flukicide.

ATCvet code:QP54AA51.

5.1 Pharmacodynamic properties

Ivermectin is a broad-spectrum endectocide of the avermectin family. Ivermectin is isolated after purification and hydrogenation of the avermectin-family compounds which are obtained from the fermentation of the soil organism Streptomyces avermitilis.

Ivermectin is a macrocyclic-lactone derivative which has a broad and potent antiparasitic activity against nematodes and arthropods. It acts by inhibiting nerve impulses. Ivermectin binds selectively and with high affinity to glutamate-gated chloride-ion channels which occur in invertebrate nerve and muscle cells. This leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarization of the nerve or muscle cell, resulting in paralysis and death of the relevant parasites. Compounds of this class may also interact with other ligand-gated chloride channels, such as those gated by the neurotransmitter gamma-aminobutyric acid (GABA). The margin of safety for compounds of this class is attributable to the fact that mammals do not have glutamate-gated chloride channels. The macrocyclic lactones have a low affinity for other mammalian ligand-gated chloride channels and they do not readily cross the blood-brain barrier.

Clorsulon inhibits glycolytic enzymes of Fasciola hepatica(3-phosphoglycerate kinase and phosphoglyceromutase). This enzymatic inhibition effectively blocks the Embden-Myerhof glycolytic pathway and thereby deprives the fluke of its main source of metabolic energy.

5.2 Pharmacokinetic particulars

After subcutaneous injection of the product at the dose of 1 ml per 50 kg (200 µg/kg of ivermectin and 2 mg/kg of clorsulon), mean maximum concentrations of 26 ng/ml for ivermectin and 2.8 µg/ml for clorsulon were reached at 35 hours for ivermectin and 9 hours for clorsulon.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

- Propyl gallate (E310)

- Disodium edetate

- Glycerol formal

- Propylene glycol

- Water for injections.

6.2 Incompatibilities

None known.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf life after first opening the immediate packaging: 28 days.

6.4 Special precautions for storage

Protect from light.

Store in the original container.

Following withdrawal of the first dose, use the product within 28 days.

6.5 Nature and composition of immediate packaging

Size 50 ml, 200 ml, 500 ml and 1000 ml, colourless LDPE vials with chlorobutyl rubber stopper and aluminium overseal. Not all packs may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

EXTREMELY DANGEROUS to fish and aquatic life. Do not contaminate ponds, waterways or ditches with the product or empty container.

7. MARKETING AUTHORISATION HOLDER

Virbac S.A.

1ère avenue , 2065m - LID

06516 Carros

Cedex

France

8. MARKETING AUTHORISATION NUMBER

Vm:05653/4155

9. DATE OF FIRST AUTHORISATION

Date:15 December 2011

10. DATE OF REVISION OF THE TEXT

Date: October 2014

APPROVED 10/10/14